Drug Addiction – Pipeline Review, H2 2012

Drug Addiction – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Drug Addiction - Pipeline Review, H2 2012', provides an overview of the Drug Addiction therapeutic pipeline. This report provides information on the therapeutic development for Drug Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Drug Addiction. 'Drug Addiction - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Drug Addiction.
- A review of the Drug Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Drug Addiction pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Drug Addiction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Drug Addiction therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Drug Addiction Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Drug Addiction 7
Drug Addiction Therapeutics under Development by Companies 9
Drug Addiction Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Drug Addiction Therapeutics – Products under Development by Companies 14
Drug Addiction Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Drug Addiction Therapeutics Development 16
Alkermes, Inc. 16
Catalyst Pharmaceutical Partners, Inc. 17
Biotie Therapies Corp. 18
KYORIN Pharmaceutical Co., Ltd. 19
Drug Addiction – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
Nepicastat - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Ketas - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CPP-109 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Modafinil - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Emend - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Chantix - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ALKS 5461 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Vaccine For Cocaine Addiction - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Ch-mAb7F9 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Drug Addiction Therapeutics – Drug Profile Updates 40
Drug Addiction Therapeutics – Discontinued Products 45
Drug Addiction Therapeutics - Dormant Products 46
Drug Addiction – Product Development Milestones 47
Featured News & Press Releases 47
Jul 12, 2012: Catalyst Pharma Partners To Announce Top-Line Data From CPP-109 Phase II(b) Clinical Trial For Treatment Of Cocaine Addiction 47
Jun 28, 2012: Catalyst Pharma Announces Publication Of Vigabatrin Data For Treatment Of Cocaine Addiction in Online Edition of American Journal of Ophthalmology 47
May 22, 2012: Catalyst Reports Positive Results From Phase I Clinical Study Of CPP-115 48
Jan 31, 2012: Catalyst Pharmaceutical Partners To Present CPP-115 Progress At 2012 Epilepsy Pipeline Update Conference 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products Under Development for Drug Addiction, H2 2012 7
Products under Development for Drug Addiction – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Alkermes, Inc., H2 2012 16
Catalyst Pharmaceutical Partners, Inc., H2 2012 17
Biotie Therapies Corp., H2 2012 18
KYORIN Pharmaceutical Co., Ltd., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Drug Addiction Therapeutics – Drug Profile Updates 40
Drug Addiction Therapeutics – Discontinued Products 45
Drug Addiction Therapeutics – Dormant Products 46

List of Figures
Number of Products under Development for Drug Addiction, H2 2012 7
Products under Development for Drug Addiction – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24